研究单位：[1]Abbisko Therapeutics Co, Ltd[2]Precision NextGen Oncology,Beverly Hills,California,United States,90212[3]Anhui Chest Hospital,Hefei,Anhui,China[4]Fujian Cancer Hospital,Fuzhou,Fujian,China[5]The first Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Harbin,China[6]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China[7]Henan Cancer Hospital,Zhengzhou,Henan,China[8]Union Hospital Tongji Medical College Huzhong University of Science and Techology,Wuhan,Hubei,China[9]Hunan Cancer Hospital,Changsha,Hunan,China[10]The first Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China[11]Jilin Cancer Hospital,Changchun,Jilin,China[12]Central Hospital Affiliated to Shangdong of First Medical University,Jinan,Shandong,China[13]Shanghai Chest Hospital,Shanghai,Shanghai,China[14]Sichuan Cancer Hospital,Chengdu,Sichuan,China[15]Zhejiang Caner Hospital,Hangzhou,Zhejiang,China
研究目的：
This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of ABSK112 in patients with NSCLC to evaluate the safety, tolerability, PK, and preliminary antitumor efficacy.
